ProCE Banner Activity


New Options for Management of Refractory ITP

Podcast Episodes

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by the increased destruction of platelets. Individuals with chronic or persistent ITP need alternatives to corticosteroids. In this second of 2 podcasts, listen as 2 experts discuss novel therapies that target disease pathophysiology, with a focus on individualizing treatment to optimize outcomes for their patients with ITP.

To access episode 1, click here.

Physician Assistants: maximum of 0.25 hours of AAPA Category 1 CME credits Registered Nurses: 0.25 Nursing contact hours, includes 0.25 hour of pharmacology credit

Released: April 05, 2022

Expiration: April 04, 2023

No longer available for credit.



Hanny Al-Samkari

Hanny Al-Samkari, MD

Assistant Professor
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts

Christopher Nelson

Christopher Nelson, ACNP-BC, MBA

Nurse Practitioner
Hematology and Oncology
Avera Cancer Institute
Avera St. Luke's Hospital
Aberdeen, South Dakota


This activity is supported by educational grants from Dova Pharmaceutials, Inc. and Novartis Pharmaceuticals Corporation.

Provided by

ProCE Banner


Dova Pharmaceuticals

Novartis Pharmaceuticals Corporation

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe novel therapies for management of refractory ITP

  • List factors to consider in the selection of therapy for ITP


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Dr Al-Samkari: consultant/advisor/speaker: Argenx, Forma, Moderna, Novartis, Rigel; consultant/research funding (paid to institution): Agios, Amgen, Dova/Sobi.

Mr Nelson: consultant/advisor/speaker: Amgen, AbbVie, AstraZeneca, Bristol-Myers Squibb/Celgene, Beigene, Incyte, Karyopharm, Rigel, Sanofi.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. Listen to the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the post-test and evaluation form

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 100%.

The estimated time to complete this activity is 0.25 hours.

Release date: April 5, 2022
Expiration date: April 4, 2023




The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.



Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 0.25, which includes 0.25 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until April 4, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.